Group 1: E-commerce Development - The company has explored various models for its pharmaceutical e-commerce and established partnerships with e-commerce solution providers to advance its business [2] - The strategy involves leveraging retail physical stores and internet technology to enhance service capabilities for consumers [2] - The company will monitor national policy changes and align its e-commerce development with market demands [2] Group 2: Inventory and Logistics Management - The company has implemented the SAP WMS (Warehouse Management System) to optimize inventory distribution and ensure timely supply to stores [3] - The logistics system integrates various management functions, including inventory, order, and reverse logistics management [4] - The logistics infrastructure includes advanced equipment such as high racks, automated transmission systems, and RF mobile terminals [4] Group 3: Operational Processes - The inbound process utilizes MRP (Material Requirements Planning) for effective delivery management and quality checks through RF mobile terminals [4][5] - The replenishment process involves strict management of whole and split items, with 100% of items requiring split operations and 85% of outbound items being consolidated [5] - The picking process employs 130 RF mobile terminals for efficient, accurate, and paperless operations [6] Group 4: Review and Shipping Processes - The review process is conducted using RF mobile terminals, ensuring accurate verification and packaging of items [6] - The shipping process includes 52 outbound sorting lines, with automated scanning and allocation of packages to designated delivery points [7] - The MRP data calculation for replenishment is based on historical sales data to forecast future demand and optimize inventory levels [7]

Store Growth and Profitability - New stores begin normal operations from the third month and achieve profitability by the 12th month, with cumulative profitability reached by the 26th month [1] - The company has experienced a 30% profit growth over the past three years, primarily from the maturation of existing stores and enhanced brand collaboration [1] Expansion Plans - The company aims to strengthen its market position in Yunnan and expand into Sichuan, Guangxi, Guizhou, Chongqing, and Shanxi, targeting to become one of the top three pharmaceutical retail chains in China [1] - Focus on direct retail chain expansion and improving logistics and supply chain integration to enhance scale benefits [1] Brand Collaboration and Supply Chain Integration - As of December 31, 2013, the company had over 2,300 direct chain stores and 1,194 co-branded products, with the top 100 products accounting for nearly 50% of sales [3][4] - The company directly procures from manufacturers, benefiting from lower prices and favorable terms, with over 60% of total sales coming from direct purchases from manufacturers [5] E-commerce Environment and Practices - The online pharmaceutical market in China was valued at 42.6 billion yuan in 2013, with significant policy changes expected to boost e-commerce growth [6] - The company is exploring e-commerce models, including a website with nearly 3,000 products and partnerships with third-party platforms like Tmall [7] - O2O practices are being implemented in select stores to enhance customer experience and integrate online and offline sales [7]

投资者关系活动记录表 1 证券代码：002727 证券简称：一心堂 云南鸿翔一心堂药业（集团）股份有限公司投资者关系活动记录表 编号：TG1409-003 | --- | --- | --- | |------------------------|------------------------|----------------------------------------------------------| | | | | | 投资者关系活动 | ■ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | ■ 其他 （电话会议） | | | 参与单位名称及 | 国泰君安、国信证券等 | 125 人 | | 人员姓名 | | | | 时间 | 2014 年 9 月 10 | 日 16： 00-17：00 | | 地点 | | 云南鸿翔一心堂药业（集团）股份有限公司会议室 | | 上市公司接待人 | | 公司董事、 董事会秘书、副总裁、财务负责人 田俊，证券事务 | | 员姓名 | | 代表、证券 ...

Group 1: Store Operations and Profit Growth - New stores begin normal operations from the third month, achieving profitability by the 12th month and fully recovering losses by the 26th month [1] - The company's overall profit has grown by approximately 30% over the past three years, primarily due to the maturation of existing stores and enhanced management capabilities [2] Group 2: Gross Margin and Supplier Relationships - High gross margins are achieved through various supplier cooperation models, including national and regional distribution, which significantly impact profit margins [2] - Direct procurement from manufacturers allows the company to earn both channel and retail margins, further increasing overall profitability [3] Group 3: O2O Development and E-commerce Strategy - The company is exploring O2O business models and has partnered with SAP Hybris and Infosys Lodestone to enhance its e-commerce capabilities [4] - The official website features nearly 3,000 products across various categories, including Western and traditional Chinese medicine, medical devices, and health supplements [4] - The company has established three online stores on Tmall, maintaining good ratings in service and delivery [5] Group 4: Product Strategy and Market Positioning - The company focuses on providing affordable traditional Chinese medicine, sourcing raw materials directly from origin to minimize costs [6] - The "Cordyceps and Ginseng" store is designed as a flagship for traditional Chinese medicine, differing in product structure and customer targeting from standard pharmacies [7]

云南鸿翔一心堂药业（集团）股份有限公司 投资者调研会议记录 时间：2014 年 9 月 19 日 地点：云南鸿翔一心堂药业（集团）股份有限公司会议室 召开方式：电话访谈交流 投资者：光大证券等 25 人 接待人：公司董事、 董事会秘书、副总裁、财务负责人 田俊 参加人员：证券事务代表、证券总监 代四顺，信息总监兼平台 电商事业部总经理 李文程 一、公司情况介绍（田俊） 公司在公告中披露了在电商业务中的进展，公司开展电商比较早，拿证比较早，在官 网、淘宝、天猫、OTO 四个渠道都有进展。以 SAP 系统为核心，可以说公司是开展电商最早 的公司之一，SAP 系统在中国电商中使用较多，以一心堂最早使用，其他医药电商也有使 用。现在和大家探讨下医药电商行业的发展。 二、问答环节 1. 田总如何看待目前医药电商行业的发展情况？ 答：电商要有耐心，医药电商现在规模 46 亿，行业 2400 亿，2%不到。明年预测 68 亿， 占比 2%。OTO 替代率在 5%以下，医药销售还是以线下为主。美国医疗线下销售 83%，网 上替代网下 17%。并且线上部分也不全是邮寄，还有很大部分是店面取药。并且美国政策 上是医药分家，利于网 ...

云南鸿翔一心堂药业（集团）股份有限公司 投资者调研会议记录 时间：2015 年 08 月 19 日 地点：云南鸿翔一心堂药业（集团）股份有限公司会议室 召开方式：现场交流 投资者：华创证券 王逸萌、沈晓瑜，交银施罗德基金 沈楠，兴 业全球基金 钟明 接待人：证券事务代表、证券总监 代四顺 参加人员: 证券副总监李正红、证券部经理阴贯香 问题一，公司收购情况介绍？ 答：公司今年四月份以来，进行了海南联合广安堂药品超市连锁经营有限公司 100% 股权收购、山西长城药品连锁有限公司门店收购、山西白家老药铺连锁药店有限公司门店收 购、晋中市泰来大药房有限公司门店收购、山西百姓平价大药房连锁有限公司门店收购、广 西百色博爱医药连锁有限公司门店收购、四川省蜀康医药连锁有限公司门店收购、四川省田 燕梅女士个体经营药店收购、桂林市桂杏霖春药房连锁有限公司门店收购。目前，海南公司 已完成工商变更，山西吕梁百姓平价、晋中泰来、山西白家老药铺三家已完成门店交接，其 他几家正在办理交接过程中。海南公司是二季度纳入上市公司合并报表范围，其他几个收 购项目是资产收购，销售会在收购主体公司下半年的损益中体现出来。截止到 2015 年 6 ...

Group 1: Investor Relations Activity - The activity involved a specific audience survey and a site visit [1] - Participants included representatives from various financial institutions such as Shenwan Hongyuan and Agricultural Bank of China [1] - The event took place on September 10, 2015, from 09:00 to 12:00 [1] Group 2: Company Representatives - Company representatives included the Secretary of the Board and Financial Officer Tian Jun, along with other key personnel [1] - The meeting was held in the conference room of Yunnan Hongxiang Yixintang Pharmaceutical (Group) Co., Ltd. [1] Group 3: Main Content of the Activity - The main focus was on business development discussions and site tours [1] - A record of questions and discussions from the site visit was documented [1]

Group 1: Investor Relations Activity - The investor relations activity was a telephone conference with specific target research [1] - The event involved 94 participants from various investment firms [1] - The meeting took place on August 15, 2015, from 20:00 to 22:00 [1] Group 2: Company Representatives - The meeting was hosted by Tian Jun, the Vice President and Financial Officer of Yunnan Hongxiang Yixintang Pharmaceutical Group [1] - Other company representatives included board members and the board secretary [1] Group 3: Meeting Content - The main topics discussed included the company's mid-year report and progress on mergers and acquisitions [1] - Meeting materials included minutes and a list of participating units [1]